Drug
Vabicaserin clinical trials
Includes 6 studies of Vabicaserin hydrochloride.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Name
- vabicaserin
- 3
Studies by the year they started
9 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Wyeth is now a wholly owned subsidiary of Pfizer (8) · Pfizer (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses vabicaserin is read from its arms, and is right about nine times in ten.
Testing it · 9
- Study Evaluating Vabicaserin in Subjects With SchizophreniaCompletedPhase 2PfizerNCT00563706Written as vabicaserin
- Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of SchizophreniaWithdrawnPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00768612Written as SCA-136 50mg/day
- Comparative Formulation Study of VabicaserinCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00928551Written as vabicaserin
- Safety, PK and PD Study in Healthy Male Japanese SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00447941Written as SCA-136
- Study Evaluating SCA-136 in Subjects With Acute Exacerbations of SchizophreniaCompletedPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00265551Written as SCA-136 (200 mg)
- Study Evaluating SCA-136 Tolerability With Dose Titration and FoodTerminatedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00420706Written as SCA-136
- Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00505973Written as SCA-136
- Study Comparing Bioavailability of Oral Formulations of VabicaserinCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00541996Written as vabicaserin
- Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00458107Written as SCA-136
Codes
What other systems call vabicaserin · ClinicalTrials.gg INT005788
- MeSH (NLM) C556517vabicaserinOne source NLM
- UNII (FDA) WD9550HPNLVABICASERINConfirmed FDA, NLM, Wikidata
- Wikidata Q7907856vabicaserinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C132725VabicaserinOne source FDA
- DrugBank DB12071One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C556517 | vabicaserin | One source NLM |
| UNII (FDA) | WD9550HPNL | VABICASERIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7907856 | vabicaserin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C132725 | Vabicaserin | One source FDA |
| DrugBank | DB12071 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.